Spots Global Cancer Trial Database for Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Official Title: PSMA-directed Targeted Alpha Therapy With FPI-2265 (225Ac-PSMA-I&T) for the Treatment of Metastatic Castration-resISTant Prostate Cancer (TATCIST). A Phase II Clinical Trial.
Study ID: NCT05219500
Interventions
Study Description
Brief Summary: The treatment regimen will consist of 4 doses of FPI-2265
Detailed Description: The treatment regimen will consist of 4 doses of FPI-2265, administered at 8 ± 1 week intervals, with an initial activity of 100 kilobecquerel (kBq)/kg (±10%). Additional doses will be administered at 100 kBq/kg (±10%) with the following exceptions: * Participants who experience dose-modifying events. * Participants with a confirmed decline in PSA\>=50%.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
XCancer Omaha/Urology Cancer Center, Omaha, Nebraska, United States
Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States
Contact Details
Name: Keith Barnett
Affiliation: Fusion Pharmaceuticals Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
